Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996806 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL7978226 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL9359626 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL10795076 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL497178 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL24866537 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL9587111 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL21148 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL10348708 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL436440 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598479-B1 | A METHOD FOR PREPARING RAMIPRIL | AARTI HEALTHCARE LTD (IN) | 2015-04-01 | — | — | EP | claimed |
| US-5175306-A | Intermediates for hypotensive agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-12-29 | — | — | US | claimed |
| EP-0115345-B1 | PROCESS FOR THE RESOLUTION OF RACEMIC OPTICALLY ACTIVE BICYCLIC IMINO-ALPHA-CARBOXYLIC ACID ESTERS AND USE OF THE COMPOUNDS OBTAINABLE IN THIS WAY FOR THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-07 | — | — | EP | claimed |
| WO-2023280280-A1 | FUSED-RING COMPOUND THAT ACTS AS KRAS G12D INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10100072-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-7935831-B2 | Process for the preparation of 2-azabicyclo[3.3.0]octane-3-carboxylic Acid Derivatives | EVONIK DEGUSSA GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20090306404-A1 | Process for the Preparation of 2-azabicyclo[3.3.0]octane-3-carboxylic Acid Derivatives | DEGUSSA GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1861368-B1 | PROCESS FOR THE PREPARATION OF 2-AZABICYCLOÝ3.3.0¨OCTANE-3-CARBOXYLIC ACID DERIVATIVES | EVONIK DEGUSSA GMBH (DE) | 2009-02-18 | — | — | EP | disclosed |
| EP-1861368-A1 | PROCESS FOR THE PREPARATION OF 2-AZABICYCLOÝ3.3.0¨OCTANE-3-CARBOXYLIC ACID DERIVATIVES | Evonik Degussa GmbH (DE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100168-A1 | PROCESS FOR THE PREPARATION OF 2-AZABICYCLO[3.3.0]OCTANE-3-CARBOXYLIC ACID DERIVATIVES | DEGUSSA GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
| US-5011940-A | Process for the preparation of bicyclic amino carboxylic acids, intermediates in this process, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-04-30 | — | — | US | disclosed |
| US-4831157-A | OCRAHYDROCYCLOPENTA(B)PYRROLE-2-CARBOXYLATE | SCHERING CORPORATION (US) | 1989-05-16 | — | — | US | disclosed |
| US-4587258-A | HYPOTENSIVE AGENTS, CONGESTIVE HEART FAILURE | SCHERING CORPORATION (US) | 1986-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100072-B2 | Phosphonate compounds for treatment of complement mediated disorders | CFD, TFPI, C1QBP | CYP2D6 4762/4885LMNA 1958/4885BLM 3380/4885 |
| US-20090306404-A1 | Process for the Preparation of 2-azabicyclo[3.3.0]octane-3-carboxylic Acid Derivatives | AZI2, CYP11B2, CYP51A1 | CYP2D6 30/4885LMNA 3098/4885BLM 4100/4885 |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | CFD, TFPI, C1QBP | CYP2D6 4762/4885LMNA 1958/4885BLM 3380/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | CYP2D6 4762/4885LMNA 1958/4885BLM 3380/4885 |
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | CYP2D6 4762/4885LMNA 1958/4885BLM 3380/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | CYP2D6 4762/4885LMNA 1958/4885BLM 3380/4885 |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | CFD, TFPI, CFH | CYP2D6 3079/4885LMNA 1300/4885BLM 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.